Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase NA 1Phase EARLY_PHASE1 1

Status

Recruiting 4Active not recruiting 1

Sponsor Class

OTHER 3INDUSTRY 2

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 22Genitourinary 16Breast 15Gynecologic 5Thoracic 3Other solid neoplasm 2Tumor-Agnostic 1Head & Neck 1

Conditions

Uterine Cervical Neoplasms 2Ovarian Neoplasms 2Ovarian Cancer Recurrent 1Head and Neck Neoplasms 1Endometrial Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Paclitaxel 581Carboplatin 528Cisplatin 359Bevacizumab 256pembrolizumab 228Gemcitabine 157liposomal doxorubicin 132Topotecan 131olaparib 129Cyclophosphamide 128Radiotherapy 118Taxes 114Docetaxel 95Brachytherapy 94Drug Therapy 91niraparib 88Doxorubicin 86Surveys and Questionnaires 85Magnetic Resonance Spectroscopy 80Blood Specimen Collection 74Nivolumab 71Specimen Handling 70Hyperthermic Intraperitoneal Chemotherapy 64Biopsy 63fludarabine 57Filgrastim 53Letrozole 50Oxaliplatin 49durvalumab 47Immunoglobulin G 47

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
disitamab vedotin × Gynecologic × Clear all
NCT06003231 2026-06-01

A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2

Seagen Inc.

Phase 2 Active not recruiting
120 enrolled
GynecologicHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT06540729 2025-07-08

DAB

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 2 Recruiting
39 enrolled
Gynecologic

Ovarian Neoplasms

NCT06558682 2025-04-01

Neoadjuvant Therapy in Cervical Cancer

Qilu Hospital of Shandong University

Phase NA Recruiting
48 enrolled
Gynecologic

Uterine Cervical Neoplasms

NCT06660511 2024-10-28

Exploratory Study on the Safety and Efficacy of Disitamab Vedotin in Combination with Anlotinib Hydrochloride for the Treatment of HER-2-expressing Recurrent Platinum-resistant Ovarian Cancer.

Second Xiangya Hospital of Central South University

Phase EARLY_PHASE1 Recruiting
5 enrolled
Gynecologic

Ovarian Cancer Recurrent

NCT06155396 2024-02-28

A Study of RC48-ADC Combination With Zimberelimab Injection Therapies at Least First-line Platinum-containing Standard Therapy Failed With Recurrent or Metastatic Cervical Cancer

RemeGen Co., Ltd.

Phase 2 Recruiting
116 enrolled
Gynecologic

Uterine Cervical Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡